Akiyama Yasuto, Maruyama Kouji, Watanabe Morihiro, Yamaguchi Ken
Growth Factor Division, National Cancer Center Research Institute, 5-1-1 Tsukuji, Chuo-ku, Tokyo 104-0045, Japan.
Int J Oncol. 2002 Sep;21(3):509-14.
Genetically modified dendritic cells (DCs) with Th1 type cytokine genes are useful for activating anti-tumor immune response. We made human interleukin (IL)-12 p70 gene-transduced DCs generated from CD34+ progenitor cells using a retrovirus system and investigated the function of IL-12-producing DCs. We used the pMX retroviral vector and made cytokine gene-containing viral vectors referred to as GFP pMX and hIL-12 pMX. Supernatants from BOSC23 cells transfected with GFP pMX and hIL-12 pMX were harvested and used for transfection of DC. Cord blood CD34+ cells were incubated with supernatants containing retrovirus for 48 h with cytokines such as IL-3, IL-6, SCF, Flt3 ligand (FL), bFGF and IGF-I. The cells were cultured for 12 days in the presence of GM-CSF, SCF, FL, IL-4 and TNF-alpha to get mature DC-enriched population. Analysis of surface marker on DCs and allogeneic MLR assay were also performed. After a 14-day culture, 60-70% of cultured CD34+ cells were DC marker (CD1a, DEC205) positive. The IL-12 p70 protein levels in supernatant of DC-GFP and DC-hIL-12 were 0.2 ng/ml and 53 ng/ml/5 x 10(5) DCs for 72 h, respectively. The addition of CH296 fibronectin fragment (FN) increased 3-fold IL-12 gene transduction efficiency into DCs. MLR assay showed that IL-12-producing DC exhibited more potent T cell growth-stimulating activity compared with GFP-DC. These results suggested that genetically modified CD34+ cell-derived DCs with human IL-12 gene are fully efficient in T cell priming, and could be a good tool for effective cancer immunotherapy.
携带Th1型细胞因子基因的基因修饰树突状细胞(DCs)可用于激活抗肿瘤免疫反应。我们使用逆转录病毒系统制备了由CD34+祖细胞产生的人白细胞介素(IL)-12 p70基因转导的DCs,并研究了产生IL-12的DCs的功能。我们使用pMX逆转录病毒载体,制备了含细胞因子基因的病毒载体,即GFP pMX和hIL-12 pMX。收集用GFP pMX和hIL-12 pMX转染的BOSC23细胞的上清液,用于DCs的转染。将脐血CD34+细胞与含有逆转录病毒的上清液以及IL-3、IL-6、SCF、Flt3配体(FL)、bFGF和IGF-I等细胞因子一起孵育48小时。在GM-CSF、SCF、FL、IL-4和TNF-α存在的情况下,将细胞培养12天,以获得富含成熟DCs的群体。还进行了DCs表面标志物分析和同种异体混合淋巴细胞反应(MLR)测定。经过14天的培养,60%-70%的培养CD34+细胞为DC标志物(CD1a、DEC205)阳性。DC-GFP和DC-hIL-12上清液中IL-12 p70蛋白水平在72小时内分别为0.2 ng/ml和53 ng/ml/5×10(5)个DCs。添加CH296纤连蛋白片段(FN)可使IL-12基因转导DCs的效率提高3倍。MLR测定表明,与GFP-DC相比,产生IL-12的DC表现出更强的T细胞生长刺激活性。这些结果表明,携带人IL-12基因的基因修饰CD34+细胞来源的DCs在T细胞启动方面具有充分的效率,并且可能是有效的癌症免疫治疗的良好工具。